News | Stents Drug Eluting | January 25, 2018

Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice

Vascular intervention / BIOFLOW-V trial confirms leading clinical performance for Orsiro; new Magmaris data presents potentially lower risk of neoatherosclerosis formation

Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice

January 25, 2018 – Data presented at the Biotronik-sponsored symposium on the Orsiro drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris reinforce the case that the magnesium-based resorbable technology does not share the same risk of acute and late scaffold thrombosis as the controversial poly-L-lactide (PLLA) alternative.

Jacques Koolen, cardiologist at Catharina Hospital, Eindhoven, Netherlands, and co-principle investigator and steering committee member of the BIOFLOW-V study, presented the latest addition to Orsiro’s body of clinical evidence. In this large international study, Orsiro reached unequivocal non-inferiority in the primary endpoint of target lesion failure (TLF) at 12 months versus Xience (6.2 percent vs 9.6 percent, p=0.04). Furthermore, a post-hoc superiority analysis demonstrated a 96.9 percent probability of Orsiro being superior to Xience in terms of TLF at 12 months.

William Wijns, professor of interventional cardiology at the Lambe Institute for Translational Medicine, Galway, Ireland, explored the question: why do we need scaffolds? “While recognizing the limitations of currently available resorbable scaffolds, we must also acknowledge that DESs still show progression of events in the late follow-up,” Wijns stated. “The goal of resorbable scaffolds is not only to decrease or eliminate those late events but also to restore the vessel anatomy and functionality, to restore a low thrombogenic milieu and potentially eliminate neoatherosclerosis.”

Finally, Michael Joner, professor of interventional cardiology at the German Heart Center, Munich, Germany, presented new Magmaris preclinical results. As Magmaris still reports zero percent definite and probable scaffold thrombosis in clinical trials, Joner presented new results on the formation of neoatherosclerosis with Magmaris compared to a stainless steel equivalent with identical design. The results demonstrate that Magmaris shows significantly lower levels of lipid-laden foamy macrophages – a sign of early neoatherosclerosis, compared to the stainless steel version.

“These results once more lead us to believe that the backbone material might be influencing the outcomes, and that vascular restoration occurs early in Magmaris allowing for compensatory vessel remodeling,” stated Joner.

For more information: www.biotronik.com/en-us

Related Content

Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.